TOT BIOPHARM-B(01875) reported a 49% year-on-year increase in revenue to RMB 809 million in the first three quarters.
Dongyao Pharmaceutical-B (01875) announced that, for the nine-month period ending on September 30, 2024, the Group's operating...
TOT BIOPHARM-B (01875) announced that during the nine-month period ending on September 30, 2024, the Group's operating income increased by 49% year-on-year to RMB 809 million, mainly due to the steady growth of sales of self-developed products and CDMO/CMO business. Net profit reached RMB 35.403 million.
Related Articles
Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.
Industrial: Hong Kong stock market sentiment index has reached the bottom area.
"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"
Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.
Industrial: Hong Kong stock market sentiment index has reached the bottom area.
"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"
RECOMMEND
Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026
Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026
Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026
